A bdominal aortic aneurysm (AAA) is a common, asymptomatic condition with a prevalence of 1.2% to 4% in people >50 years of age. [1] [2] [3] [4] If left untreated, AAA progresses to rupture unless death occurs for another reason. The risk of rupture is closely related to aneurysmal size 5, 6 with a high short-term mortality rate of 76%. 7, 8 The progression of AAA is characterized by degradation and remodeling of the arterial extracellular matrix. Known risk factors for AAA are age, male sex, smoking, family history of AAAs, and comorbidities such as hypertension, atherosclerotic disease, and hypercholesterolemia.
A bdominal aortic aneurysm (AAA) is a common, asymptomatic condition with a prevalence of 1.2% to 4% in people >50 years of age. [1] [2] [3] [4] If left untreated, AAA progresses to rupture unless death occurs for another reason. The risk of rupture is closely related to aneurysmal size 5, 6 with a high short-term mortality rate of 76%. 7, 8 The progression of AAA is characterized by degradation and remodeling of the arterial extracellular matrix. Known risk factors for AAA are age, male sex, smoking, family history of AAAs, and comorbidities such as hypertension, atherosclerotic disease, and hypercholesterolemia. 3, [9] [10] [11] AAAs have traditionally been considered solely as a manifestation of atherosclerosis in the abdominal aorta, and it was believed that the usual risk factors, including diabetes mellitus, were involved. However, the Aneurysm Detection and Management screening study reported in 1997 the remarkable finding that diabetes mellitus reduced the prevalence of AAA by almost half, 1 and later studies confirmed this finding. [12] [13] [14] [15] The mechanism underlying this paradoxical association is unknown but may be related to hyperglycemia, 16 other factors in the diabetic milieu, or the effects of antidiabetics. 17 The pathology of the arterial wall in diabetes mellitus includes not only the occurrence of atherosclerotic plaques but also a series of generalized alterations, for example, endothelial dysfunction, 18 increased arterial stiffness, 19 medial calcifications, 20 and changes in the extracellular matrix. [21] [22] [23] [24] In relation to the formation of aneurysms, it is of interest that the compensatory remodeling, which occurs in atherosclerotic arteries, is seemingly not functional in diabetes mellitus. Instead of compensatory enlargements because of remodeling, coronary arteries from individuals with diabetes mellitus showed shrinkage as a response to the appearance of atherosclerotic plaques. 25, 26 It is likely that these generalized arterial changes are involved in the decreased risk of AAA among individuals with diabetes mellitus.
The aim of this study was to increase our understanding of the paradoxically protective role of diabetes mellitus on AAAs. Our hypothesis was that the growth of AAAs is associated with the glycemic status and not only with the presence of diabetes mellitus itself. We investigated the association between glycated hemoglobin (HbA1c) and the growth rate, maximal anterior-posterior diameter, and stiffness in screening-diagnosed small AAAs in both individuals with and without self-reported diabetes mellitus. We found an inverse association between the growth rate of AAAs and the level of HbA1c.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
The data were based on the VIVA (Viborg Vascular) randomized screening trial of men aged 65 to 74 years in the Central Denmark Region, where 319 individuals were identified with an AAA and with at least one follow-up. 27, 28 Analyses were conducted using MannWhitney U test, Spearman correlation, and mixed-effect models.
Results

Demographics
At baseline, AAAs were diagnosed in 619 men, which corresponds to a prevalence of 3.3%. Of the identified AAAs, 103 AAAs (16.7%) were ≥50 mm and 62 AAAs (10.1%) were ≥55 mm, and these 103 individuals were referred for vascular intervention or surveillance.
Of the 619 individuals with AAAs, 319 were included in our study (Figure 1 ).
Sixty-one individuals (19.1%) had diabetes mellitus (33 self-reported and 28 defined by increased HbA1c). HbA1c ranged from 28 to 77 mmol/mol. In all, 49 individuals had HbA1c >47 mmol/mol, with a range of 48 to 77 mmol/mol and a mean of 54 mmol/mol. The interpersonal coefficient of variation for HbA1c was (SD/mean %) 15.9% for the total population and 8.9% for individuals without (self-reported and defined) diabetes mellitus.
The median baseline aortic diameter was 35.0 versus 34.0 mm in individuals with and without diabetes mellitus, respectively (P=0.96). All demographic information are listed in the Table. Mean follow-up was 3.88 years (range, 0.47-5.86 years).
Association Between HbA1c and Calculated Aneurysmal Growth Rate
The median calculated growth rate was 1.7 versus 2.7 mm/y in individuals with and without defined diabetes mellitus, respectively (P<0.0001, Mann-Whitney U test). We found a statistically significant association between aneurysmal growth rate and HbA1c (Spearman ρ=−0.177; P=0.002) in the total study population.
Main Analysis Using Mixed-Effect Model
HbA1c was analyzed in tertiles in our mixed-effect model. Group 1 HbA1c ranged from 28 to 39 mmol/mol; group 2 from 40 to 43 mmol/mol; and group 3 from 44 to 77. We found a statistically significant difference between the change in aneurysmal diameter in individuals in the highest third HbA1c group compared with individuals in the lowest third HbA1c group in the crude model (P<0.000).
The following confounders were included in the mixed model adjusted analysis: (1) smoking status yes/no (former and never smoker were grouped as one in the analysis), (2) age, (3) body mass index, (4) baseline aortic measurement, (5) diastolic blood pressure, (6) level of total cholesterol, (7) presence of peripheral arterial disease, and (8) use of medication (self-reported) suspected to influence the growth rate (statins, aspirin, and β-blockers).
When adjusting for covariates, the decrease in growth was still statistically significant (P<0.000). After adjustment, aortas were 0.9 mm (confidence interval [CI], −1.71 to −0.03; P=0.04) smaller after 13 months in the highest HbA1c-tertile group compared with the lowest HbA1c-tertile group. After 3 years, the difference was a reduction of 1.8 mm (CI, 0.99-2.65; P<0.000) for the highest HbA1c-tertile group compared with the lowest HbA1c-tertile group (Figure 2 ).
In the subgroup analysis also using mixed-effect model, we analyzed individuals with and without self-reported diabetes mellitus. The HbA1c tertiles were for individuals without self-reported diabetes mellitus: group 1 HbA1c ranged from 28 to 39 mmol/mol; group 2 from 40 to 43 mmol/mol; and group 3 from 44 to 70 mmol/mol. Twenty-eight individuals (9.8%) had HbA1c >47 mmol/mol. For the group without selfreported diabetes mellitus, in which no one used antidiabetics, we found a statistically significant difference in growth between individuals in the highest and lowest HbA1c-tertile groups (P<0.000). Aortas were 0.9 mm (CI, 1.81 to −0.03; P=0.04) smaller after 21 months in the highest HbA1c-tertile group compared with the lowest HbA1c-tertile group. After 3 years, the difference was a reduction of 1.5 mm (CI, 0.59-2.42; P=0.001) for the highest HbA1c-tertile group compared with the lowest HbA1c-tertile group.
For the group with known diabetes mellitus, we analyzed HbA1c as a continuous variable because there were few observations (33 individuals). The difference in growth was not statistically significant (P=0.086). Furthermore, we found no statistically significant association between the growth after adjusting for the number of years with diabetes mellitus (P=0.093) or for the treatment for diabetes mellitus (tablets, insulin, and diet; P=0.079).
Our mixed-effect model did also show statistical significance and an inverse association when analyzing HbA1c as a continuous variable for the total population (P<0.000 for both crude and adjusted models).
Association Between HbA1c and Maximal Aneurysmal Size and Stiffness
We found no significant association between the largest anterior-posterior diameter measurement and HbA1c (Spearman ρ=−0.09; P=0. 13 We also found no significant associations between HbA1c and stiffness (ρ=−0.0001; P=0.999) or pressure strain elastic modulus (ρ=−0.002; P=0.97), nor between growth rate and stiffness (ρ=−0.06; P=0.33) or pressure strain elastic modulus (ρ=−0.06; P=0.34).
Discussion
In this prospective cohort study investigating the association between AAA and the average blood sugar level, we found that elevated levels of HbA1c were inversely associated with the aneurysmal growth rate both in the total study population and in the subgroup analysis of individuals without self-reported diabetes mellitus. However, we found no association between HbA1c and aneurysmal size or stiffness.
In the total population (self-reported diabetes mellitus+unknown (HbA1c>47) diabetes mellitus+no diabetes mellitus), we observed statistically significant relation between aneurysmal growth and HbA1c-this may be because of the effect of diabetes mellitus and antidiabetics and glycemic status itself. In the above-mentioned population minus self-reported diabetes mellitus, we observed statistically significant relation between aneurysmal growth and HbA1c-this may be because of glycemic effect (or factors related to this), but not antidiabetic treatment, because none of the individuals received diabetes mellitus-related treatment. In the population consisting of individuals with self-reported diabetes mellitus, no statistically significant relation between aneurysmal growth and HbA1c has been observed, but the reason is probably because of the small number of individuals in this group; hence, we do not focus much on results from this group.
Strengths and Limitations
Our study has several strengths. This was a unique study because we had prospective data on the level of HbA1c and the growth rate from 319 AAAs performed by specially trained nurses using a strict standardized method of measurement with reported low interobserver variability. 29 We had high-quality information about the participants because the study was conducted as a screening trial with standardized continual visits, measurements of AAAs, and questionnaires regarding medication use (although self-reported), smoking, previous illnesses, etc. Although blood samples were taken at numerous sites, HbA1c was measured at the same laboratory, thereby minimizing the risk of information bias. Furthermore, the risk of selection bias was minimal because the study was based on a randomized population-based screening trial. This is in contrast to many patient-based studies in which the slowest expanding aneurysms are under observation longer than the more rapidly expanding ones that require repair within a short time.
Our study also has some potential limitations. Although we used HbA1c, which is the telltale blood sugar measurement for the average level of blood sugar within the past 3 months, we only had one measurement per individual. Measurements from blood samples taken at each visit could have further strengthened the association between AAA growth rate and HbA1c. Furthermore, a study has shown that the withinsubject biological variation of HbA1c does not only show low intraindividual variation (1.7% in individuals with and 1.2% in individuals without diabetes mellitus). 30 In contrast, Nonfasting glucose, mmol/L* (6.4) 6.8 (7.2) (6.2) 6.6 (6.9) (7.8) 8.2 (8.8) Values in parentheses are percentage unless otherwise indicated. AAA indicates abdominal aortic aneurysm; ACE, angiotensin-converting enzyme; AMI, acute myocardial infarction; HbA1c, glycated hemoglobin; and NSAID, nonsteroid anti-inflammatory drug.
*Values are median ((p25) p50 (p75)). †Comorbidity is self-reported except from peripheral arterial disease (measured by ankle-brachial index at screening). ‡Antidiabetics are not specified.
the interindividual coefficient of variation was 15.9% in our total population and 8.9 for individuals without self-reported or defined diabetes mellitus. A single measurement of HbA1c can, therefore, be assumed to be representative of each individual's glycemic level during the follow-up time in our study, although it would have been optimal to be able to include serial measurements. Blood samples were only possible in 9 out of 13 screening locations. We referred individuals with an aneurysmal diameter >5 cm for surgical evaluation, and individuals who did not undergo aneurysmal repair received continued surveillance by the vascular department, as the shorter surveillance intervals requested made it impossible to handle these individuals in the VIVA trial organization. Although this left us with only small-to-moderate aneurysms, we have no reason to think that large aneurysms react differently to hyperglycemia than smaller aneurysms. We analyzed the individuals with or without diabetes mellitus according to their baseline status. We did not have data on new onset of diabetes mellitus during the follow-up, but we assume the number is low. This leaves us with a potential small risk for overestimating the reduction in growth in the group of individuals without self-reported diabetes mellitus. Finally, we do not have any data on exercise, which leave us with a small risk of residual confounding.
Hyperglycemia and AAAs in Humans
In our study, we found a statistically significant association between aneurysmal growth rate and the level of HbA1c. Furthermore, we found a reduced change in AAA measurement for individuals in the highest HbA1c-tertile group compared with the lowest HbA1c-tertile group; after 3 years, the difference was 1.8 mm (CI, 0.99-2.65; P<0.000). When stratifying by diabetes mellitus and analyzing only individuals without self-reported diabetes mellitus, hence avoiding antidiabetic treatment as a confounder, we still noticed a statistically significant reduction of 1.5 mm (CI, 0.59-2.42; P=0.001) after 3 years for the highest HbA1c-tertile group compared with the lowest HbA1c-tertile group. This is an observational study, so we cannot conclude anything about causality. However, these findings suggest that hyperglycemia or metabolic/hormonal factors closely related to glucose levels are protective.
Our mixed-effect model did also show statistical significance and an inverse association when analyzing HbA1c as a continuous variable (P<0.000 for both crude and adjusted models).
The analysis of individuals with self-reported diabetes mellitus did not show any statistical significance. However, the numbers were small, and this analysis was probably underpowered.
To the best of our knowledge, only one study has previously investigated the association between hyperglycemia and aneurysmal growth rate. Our results are in disagreement with this study. Golledge et al 31 studied 198 individuals, of whom 20 had diabetes mellitus, and they found no association between fasting serum glucose and AAA progression. The discrepancy between our results and those of Golledge et al could be because of their use of fasting glucose rather than HbA1c. Although both of the studies only include one measurement of the level of blood sugar, HbA1c is a more accurate measurement being the average level of blood glucose over 3 months. In addition, their study included fewer participants and used less-sensitive statistics. Additionally, the standardized training and validation of the nurses making ultrasound measurements in this study showed a rather low interobserver variability of the measurements. 29 The reduced growth in relation to elevated HbA1c could be because of the formation of cross-links in the extracellular matrix after hyperglycemia, 32 although we did not find any statistically significant associations between stiffness and growth rate or HbA1c.
Experimental Hyperglycemia
A few experimental studies have attempted to explain the association between hyperglycemia and AAAs. Dua et al 16 showed that hyperglycemia was associated with reduced experimental AAA diameter in a murine model. These findings are consistent with the study by Miyama et al 33 on hyperglycemic mice with induced AAAs, which showed that hyperglycemia reduced the experimental AAA diameter compared with normoglycemic mice. Furthermore, insulin-mediated reductions in serum glucose levels partially reversed the protective effects of hyperglycemia on aneurysm progression. 33 These and the present findings suggest that hyperglycemia, rather than its treatment, retards aneurysmal progression.
In conclusion, exploring the association between AAA and diabetes mellitus, we found an inverse association between the growth rate of AAAs and the level of HbA1c, indicating that long-lasting elevated blood sugar impairs aneurysmal progression. Importantly, we extend previous findings, because we observe that this association is also present among individuals without diabetes mellitus. Specific aspects related to diabetes mellitus as, for example, treatment with antidiabetic drugs, which may influence growth rates, does of course not play a role in the group of individuals without diabetes mellitus, and our observation, therefore, strongly support the notion that the glycemic level itself (or factors related to it) is a determinant of the growth rate of AAA. The exact mechanism remains to be discovered. Elucidating the mechanism may lead to the discovery of novel medical treatments for AAA and may provide a better understanding of the arterial damaging consequences of type 2 diabetes mellitus.
